C4 Therapeutics Stock Analysis

CCCC Stock Analysis Notes

About 74.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. C4 Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 1.67. The firm had not issued any dividends in recent years. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people. For more info on C4 Therapeutics please contact Andrew MBA at 617 231 0700 or go to https://www.c4therapeutics.com.

C4 Therapeutics Investment Alerts

CCCC Largest EPS Surprises

View All Earnings Estimates

CCCC Stock Institutional Investors

Note, although C4 Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

CCCC Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 176.38 M.

CCCC Profitablity

Management Efficiency

C4 Therapeutics has return on total asset (ROA) of (0.232) % which means that it has lost $0.232 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5998) %, meaning that it created substantial loss on money invested by shareholders. C4 Therapeutics' management efficiency ratios could be used to measure how well C4 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 7, 2026, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, C4 Therapeutics' Fixed Asset Turnover is projected to slightly decrease based on the last few years of reporting.

Technical Drivers

As of the 7th of February, C4 Therapeutics owns the Information Ratio of (0.1), market risk adjusted performance of (0.21), and Variance of 21.33. C4 Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices.

C4 Therapeutics Price Movement Analysis

C4 Therapeutics Insider Trading Activities

C4 Therapeutics Outstanding Bonds

C4 Therapeutics Predictive Daily Indicators

C4 Therapeutics Forecast Models

C4 Therapeutics' time-series forecasting models are one of many C4 Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary C4 Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

C4 Therapeutics Bond Ratings

C4 Therapeutics financial ratings play a critical role in determining how much C4 Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for C4 Therapeutics' borrowing costs.

C4 Therapeutics Debt to Cash Allocation

C4 Therapeutics currently holds 65.76 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. C4 Therapeutics has a current ratio of 6.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about C4 Therapeutics' use of debt, we should always consider it together with its cash and equity.

C4 Therapeutics Total Assets Over Time

C4 Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which C4 Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

C4 Therapeutics Debt Ratio

10.0

It looks as if most of the C4 Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the C4 Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of C4 Therapeutics, which in turn will lower the firm's financial flexibility.

C4 Therapeutics Corporate Bonds Issued

CCCC Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how C4 Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CCCC shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as C4 Therapeutics. By using and applying CCCC Stock analysis, traders can create a robust methodology for identifying CCCC entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CCCC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CCCC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

C4 Therapeutics stock analysis indicators help investors evaluate how C4 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading C4 Therapeutics shares will generate the highest return on investment. By understating and applying C4 Therapeutics stock analysis, traders can identify C4 Therapeutics position entry and exit signals to maximize returns.

When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.